

CURRICULUM VITAE

Dr. Stefano Ugel



Born at Oderzo (Italy); 24 March 1980

Codice Fiscale: GLUSFN80C24F999V

Residence: via 24 Maggio n° 20, Ormelle (TV) Italy

Phone: +39 0422 745497

+39 347 9010471

email: sugel80@gmail.com

stefano.ugel@univr.it

Position: Tenure-track Assistant Professor at Department of Medicine, University of Verona

EDUCATION

Dr. Stefano Ugel has 17 years (2003-2020) of laboratory experience. He started (2003-2004) as bachelor degree student in Biology at Department of Oncology and Surgical Science University of Padova with the thesis: "*Development of an efficient vaccination protocol towards p15E antigen in prostate tumor mouse model*" (108/110). After that he was selected for PhD-program in Oncology and Surgical Science, obtaining a PhD in 2008, with the thesis "*Active and passive immunotherapeutic approaches targeting Telomerase in mouse tumor models*". This program was carried out at the Department of Oncology and Surgical Science (Prof. P. Zanovello), University of Padova. From 2008, Dr Ugel has obtained a pluriennial post-doctoral fellowship: he won PhD fellowship "Volontari Comitato Veneto" (2008-2009) supported by AIRC to complete the project "*Generation of specific Telomerase cytotoxic T lymphocytes*" at Prof. Vincenzo Bronte laboratory (IOV - Istituto Oncologico Veneto - I.R.C.C.S); next he won a PhD fellowship to complete the project "*New anti-tumor drugs able to support a better intra-tumor lymphocytes infiltration*" (2009-Oct 2010) at Prof. Vincenzo Bronte laboratory (VIMM – Venetian Institute of Molecular Medicine, University of Padova). Successively, he won a PhD fellowship for Abroad (2010) supported by AIRC to complete the project "*TEM-1 positive cells: a new target for cancer immunotherapy*" as postdoctoral researcher in George Coukos' laboratory at Ovarian Cancer Research Center (ORCR) of University of Pennsylvania, 421 Curie Boulevard 19104 Philadelphia (PA) United States (USA). Then Dr. Ugel was integrated as PhD in the project DOD BRCA "*BRCA expression in ovarian cancer*" (rif. 553952) until May 2012. Then Dr. Ugel, as senior PhD, works at Immunology Section of Department of Medicine of Verona University, managed by Prof. Vincenzo Bronte (June 2012-2016). From November 2016 to October 2019, Dr. Ugel was enrolled as Tenure-track Assistant Professor at Department of Medicine, Immunology Section of University of Verona. April 2017, Dr. Ugel obtained Abilitazione Scientifica Nazionale (ASN, bando 1532/2016, SS06/A2 for General and Clinic Pathology). From November 2019, Dr. Ugel was enrolled as Assistant Professor at Department of Medicine, Immunology Section of University of Verona.

SCIENTIFIC ACTIVITY

Dr. Stefano Ugel research is based on:

- Validation of active immunotherapeutic approaches based on different vaccination setting using DNA plasmid in association with electric gene transfer, dendritic cells pulsed with cell-lysate or peptide, emulsinated peptide and also xenogenic vaccine
- Identification of immunodominant peptide of new tumor associated antigen.
- Validation of specific immune suppressive mechanisms in tumor tolerance.
- MDSC characterization in different tumor mouse models and human setting.
- Validation of passive immunotherapeutic approaches based on adoptive antigen specific CD8⁺ T cell transfer and isolation of specific high avidity CTL.
- Validation of new drugs able to selectively eliminate cells with of regulatory abilities, such as MDSCs, to increase the efficacy of cancer immunotherapy.
- Validation of immunotherapeutic approaches able to attack tumor endothelium.
- Generation humanized immune-reconstituted (HIR) mice model to define a specific human gene signature of early pro-metastatic niche.

Dr. Stefano Ugel skills are:

- Cellular Biology: human and murine cellular culture, proliferation and cytotoxicity assays, lymphocytes isolation from spleens and tumors, in particular derivation of specific antigen CTL, transfection of cells to induce specific antigen expression, ELISA assays, ELISpot assays, cytofluorimetric analysis, such as intracytoplasmatic analysis of IFN γ . Evaluation of immune response after vaccination in mouse models in particular in prostate and melanoma tumor models. Phenotypic characterization and isolation by immunomagnetic sorting of specific cells.
- Molecular Biology: RNA and DNA extraction from different tissues, PCR, RT-PCR, Real Time PCR, gene cloning, western blot, protein purification in particular antibodies. Experience of gene expression by Affymetrix.
- Mouse handling.
- Computer skills and competences of Microsoft office tools (word, excel, power point) and also basic knowledge of graphic design applications (CorelDraw, CorelPhotoPaint, SigmaPlot, FlowJo).
- Technical practice of specific laboratory instruments: FACS CANTO, Elipot-Reader and BTX electroporator.
- Knowledge of English language.

CONGRESS ABSTRACT

- Cingarlini S., **Ugel S.**, Marigo I., De Santo C., Dolcetti L., Gallina G., Bronte V., and Zanovello P. *Preserved effective Env responsiveness in TRAMP mice*. SIICA, Ischia (Italia); 2005. **Selezionato per presentazione orale.**
- **Ugel S.**; Cingarlini S.; Mesa Pardillo C.; Cipriani B.; Mennuni C.; Cerino R.; Calvaruso F.; Scarselli E.; Iezzi M; Musiani P.; Zanovello P. and Bronte V. *Induction of telomerase-specific cytotoxic T cells by recombinant vaccines*. SIC, Bari (Italia); 2006.
- Gallina G., Dolcetti L., Serafini P., De Santo C., Marigo I., Cingarlini S., **Ugel S.**, Colombo M.P., Basso G., Brombacher F., Borrello I., Zanovello P., Bicciato S. and Bronte V. *Tumor-induced IL-4R α ⁺ inflammatory monocytes with immunosuppressive activity on CD8⁺ T cells*. SIICA, Parigi (Francia); 2006.
- Dolcetti L., Gallina G., De Santo C., Marigo I., Serafini P., Cingarlini S., **Ugel S.**, Colombo M.P., Basso G., Brombacher F., Borrello I., Zanovello P., Bicciato S. and Bronte V. *IL-4R α ⁺ is a marker of a subset cells of inflammatory monocytes with immunosuppressive activity on CD8⁺ T cells*. The Potent New Anti-Tumor Immunotherapies. Keystone Symposia on Molecular Biology, Fairmont Banff Springs. Banff (Alberta); 2007

- **Ugel S.**, Peranzoni E., Marigo I., Dolcetti L., Sonda N., Mantelli B., Papalini F., Zilio S., Mennuni C., Scarselli E., De Palma R., Zanovello P., and Bronte V. *Adoptive immunotherapy for cancer based on mTERT specific CD8⁺ T cells*. SIICA, Roma (Italia), 2008.
- Marigo I., Fernandez-Gomez A., Mandruzzato S., Francescato S., Valpione S., Perini P., Rinaldi L., Gallo P., **Ugel S.**, Zanovello P. and Bronte V. *MDSC: potential therapeutic role in autoimmune diseases*. FISM Synphosia, Roma (Italia), 2008. **Selezionato per presentazione orale**
- Martini M., Testi M.G., Pasetto M., Picchio M.C., Innamorati G., Mazzocco M., **Ugel S.**, Cingarlini, Bronte V., Zanovello P., Krampera M., Mosna F, Cestari T., Riviera A.P., Brutti N., Barbieri O, Matera L., Tridente G., Colombatti M.. and Sartoris S. *IFN- γ mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer*. 2nd European Congress of Immunology Berlino (Germania), 2009
- Dolcetti L., Peranzoni E., **Ugel S.**, Marigo I., Fernandez Gomez A., Mesa C., Geilich M., Winkels G., Traggiati E., Casati A., Grassi F. and Bronte V. *Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF*. 2nd European Congress of Immunology Berlino (Germania), 2009. **Selezionato per presentazione orale**
- **Ugel S.**, Rueter J., De Sanctis F., Scarselli E., Mennuni C., La Monica N., Coukos G. and Facciabene A. *mTERT genetic vaccine combined with chemotherapy augments antigen-specific immune response and confers tumor protection in time depended fashion*. Gene Vaccination in Cancer, Ascoli Piceno (Italia), 2011
- **Ugel S.**, Peranzoni E., Desantis G., Chioda M., Walter S., Weinschenk T., Ochando J.C., Cabrelle A., Mandruzzato S. and Bronte V. *Immune tolerance to tumor antigens occurs in a specialized environment of the spleen..* SIC, Bologna (Italia), 2012.
- Sandri S., Bobisse S., Moxley K., Lamolinara A., De Sanctis F., Boschi F., Sbarbati A., Fracasso G., Ferrarini G., Hendriks R.W., Cavallini C., Scupoli M.T., Sartoris S., Iezzi M., Nishimura M.I., Bronte V.* and **Ugel S.*** *Anti-telomerase adoptive cell therapy to target B-cell lymphocytic leukemia*. CIMT, Mainz (Germania), 2013.
- De Sanctis F., **Ugel S.**, Fassan M., Iezzi M., Boschi F., Youngkyu P., Stramucci L., Lamolinara A., Sandri S., Ferrarini G., Cristovao Borges L., Sartoris S., Sbarbati A., Tuveson D., Scarpa A. e Bronte V. *Targeting telomerase in pancreatic cancer*. NIBIT, Siena (Italia), 2014.
- **Ugel S.**, Facciponte J.G., De Sanctis F., Li C, Wang L., Nair G., Sehgal S., Raj A. ,Matthaiou E., Coukos G. and Facciabene A. *Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature*. NIBIT, Siena (Italia), 2014.
- Sandri S., Bobisse S., Moxley K., Lamolinara A., De Sanctis F., Boschi F., Sbarbati A., Fracasso G., Ferrarini G., Hendriks R.W., Cavallini C., Scupoli M.T., Sartoris S., Iezzi M., Nishimura M.I., Bronte V.* and **Ugel S.*** *Targeting B-cell lymphocytic leukemia by adoptive transfer of telomerase specific T cells*. PIVAC, Roma (Italia), 2014. **Poster premiato con encomia** vedi: Signori E, Cavallo F. *The Fourteenth International Conference on Progress in Vaccination Against Cancer (PIVAC-14), September 24-26, 2014, Rome, Italy: rethinking anti-tumor vaccines in a new era of cancer immunotherapy*. Cancer Immunol Immunother. 2015
- Sandri S., Bobisse S., Moxley K., Lamolinara A., De Sanctis F., Boschi F., Sbarbati A., Fracasso G., Ferrarini G., Hendriks R.W., Cavallini C., Scupoli M.T., Sartoris S., Iezzi M., Nishimura M.I., Bronte V.* and **Ugel S.*** *Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies*. CMIT, Mainz (Germania), 2016
- Trovato R., De Sanctis F., Fiore A., Sandri S., Sartori S., Poffe O., Anselmi C., Fracasso G, Iezzi M., Lamolinara A., Fassan M., Rusev B., Scarpa A., Boschi F., Ruggeri L.,Tuveson D., Sartoris S., **Ugel S.** and Bronte V. *Tumor-infiltrating myeloid cells in pancreatic ductal*

adenocarcinoma. Regulatory Myeloid-Suppressor Cell Conference, Philadelphia (USA), 2016.

- De Sanctis F., Fassan M, Lamolinara A., Iezzi M., Boschi F., Sbarbati A., Youngkyu P., Sandri S., Trovato R., Fiore A., Sartori S., Poffe O., Fracasso G., Anselmi C., Tuveson D, Lawlor R.T., Scarpa A., Sartoris S., **Ugel S.** and Bronte V. *Telomerase specific adoptive cell therapy in pancreatic cancer*. NIBIT, Verona (Italia), 2016.
- De Sanctis F., Fassan M, Lamolinara A., Iezzi M., Boschi F., Sbarbati A., Youngkyu P., Sandri S., Trovato R., Fiore A., Sartori S., Poffe O., Fracasso G., Anselmi C., Tuveson D, Lawlor R.T., Scarpa A., Sartoris S., **Ugel S.** and Bronte V. *Telomerase specific adoptive cell therapy in pancreatic cancer*. NIBIT, Verona (Italia), 2016.
- **Ugel S.**, Fiore A., De Sanctis F., Sandri S., Fracasso G., Trovato R., Sartoris S., Solito S., Mandruzzato S., Vascotto F., Hippen K.L., Mondanelli G., Grohmann U., Piro G., Carbone C., Melisi D., Lawlor R.T., Scarpa A., Lamolinara A., Iezzi M., Fassan M., Bicciato S., Blazar B.R., Sahin U., Murray P.J., Bronte V. *Induction of immunosuppressive functions and NF- κ B by FLIP in monocytes*. EMDS, Verona (Italia), 2018.
- Trovato R., Fiore A., Sartori S., Giugno R., Cascione L., Canè S., De Sanctis F., Poffe O., Anselmi C., Hofer F., Sartoris S., Paiella S., Salvia R., Corbo V., Lawlor R.T., Solito S., Pinton L., Mandruzzato S., Bassi C., Scarpa A., Bronte V. and **Ugel S.** *Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3*. CMIT, Mainz (Germany), 2019.
- De Sanctis F., **Ugel S.**, Fassan M, Lamolinara A., Iezzi M., Boschi F., Sbarbati A., Youngkyu P., Sandri S., Trovato R., Fiore A., Sartori S., Poffe O., Sartoris S., Fracasso G., Anselmi C., Tuveson D, Lawlor R.T., Scarpa A., Corbo V., Paiella S., Bassi C. and Bronte V. *Telomerase specific adoptive cell therapy in pancreatic cancer*. NIBIT, Verona (Italia), 2019.
- Trovato R., Fiore A., Sartori S., Canè S., Giugno R., Cascione L., Paiella S., Salvia R., De Sanctis F., Poffe O., Anselmi C., Hofer F., Sartoris S., Piro G.; Carbone C.; Corbo V., Lawlor R., Solito S., Pinton L., Mandruzzato S., Bassi C., Scarpa A.; Bronte V. and **Ugel S.** *Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3*. NIBIT, Verona (Italia), 2019.

INVITED LECTURES AND PRESENTATIONS

- **Ugel S.**, Mennuni C., Mori F., Cipriani B., Iezzi M., Pannellini T., Lazzaro D., Ciliberto G., La Monica N., Zanovello P., Bronte V., and Scarselli E. *Immunosurveillance by telomerase-based vaccination*. SIICA, Roma (Italy), 2008.
- **Ugel S.**, Peranzoni E, Piccoli M, Falisi E, Papalini F, Solito S, Cabrelle A, De Coppi P, Zanovello P, Mandruzzato S and Bronte V. *Rational and successful chemo-immunotherapy: unveiling a novel immune adjuvant property of chemotherapeutic drugs based on the perturbation of myeloid suppressor biological niche*. SIICA, Bari (Italy), 2010.
- **Ugel S.**, Facciponti J., De Sanctis F., Mitrousis N., Wang L., Nair G., Coukos G. and Facciabene A. *Gene based vaccination specific for TEM1 (Endosialin/CD248) controls tumor progression inducing a specific T cell response*. Gene Vaccination in Cancer, Ascoli Piceno (Italy), 2011.
- **Ugel S.**, Rueter J., De Sanctis F., Scarselli E., Mennuni C., La Monica N., Coukos G. and Facciabene A. *mTERT genetic vaccine combined with chemotherapy augments antigen-specific immune response and confers tumor protection in time depended fashion*. TRCCC, Seven Springs (USA), 2012.
- **Ugel S.** *Overcoming Physical Barriers to Cancer Immunotherapy*. 2nd Inflammation, Cancer and Novel Therapeutics Conference & Summer School 2012. Heraklion, Creta (Greece), 2012.
- **Ugel S.**, Peranzoni E., Desantis G., Chioda M., Walter S., Weinschenk T., Ochando J.C., Cabrelle A., Mandruzzato S. and Bronte V. *Myeloid Derived Suppressive Cells: Overcoming Physical Barriers to Cancer Immunotherapy*. InsPiRE Conference "Progress in combination therapy in cancer using novel immunomodulators", Atene (Greece), 2012.

- **Ugel S.** *Modulation of tumor microenvironment by chemotherapy.* 10th Annual Meeting, NIBIT, Certosa di Pontignano (SI) (Italy), 2012
- **Ugel S.** Terapia adottiva con cellule TERT specifiche nelle neoplasie ematologiche. Giornata SIES (Società Italiana Ematologia Sperimentale), a Verona (VR) (Italy), 2017
- **Ugel S.** Riprogrammazione genetica delle cellule dell'immunità adattativa ed innata per approcci di immunoterapia. XV Congresso SIES (Società Italiana Ematologia Sperimentale), Rimini (RN) (Italy), 2018

AWARDS AND HONORS

- November 2006: Winner of the Prize "Laura Polo" for best bachelor thesis in Oncology awarded by the University of Padova, Italy.
- August 2010: Winner winner of Start-Up Veneto 2010 "La note degli angeli" with the scientific group Safespring of University of Padova to develop an innovative technology to make water drinkable.
- September 2011: Winner of the prize as best poster of under-35 researcher awarded by Gene Vaccination in Cancer, Ascoli Piceno (Italy)
- September 2014: Winner of prize as best poster (as special mention) of under-35 research awarded by EACR at 14th International Conference on Progress in Vaccination Against Cancer (PIVAC-14), Rome (Italy) as testified by publication published in Cancer Immunol Immunother. 2015, 64(10):1349-56

PATENT

- 2015: **Ugel S.**, Sandri S., Bobisse S., Bronte V. Gene sequence encoding a mouse TCR specific for the human HLA-A2 complex and hTERT865-873 peptide and its use for engineering human T lymphocytes for adoptive cell therapy of cancer. University of Verona, 102015902339333 (PD2015A000062).
- 2017: **Ugel S.**, Fiore A., Sahin U. and Bronte V. Engineered cells for inducing tolerance. Biontech (Mainz, DE), PCT/EP2017/051068.

INTERNATIONAL SCIENTIFIC CONGRESS ORGANIZATION

- 2018, Member of scientific commitment of international congress of EMDS society (European Society of Dendritic cells and Macrophages): "The cross-road between macrophages and dendritic cells. From immunometabolism to single cell fate". 27-29 September, Verona (VR) (Italy)

GRANT

- 2018_ **MyFirst AIRC grant** supported by Associazione Italiana per la Ricerca sul Cancro (AIRC): Principal Investigator of project entitled "FLIP up-regulation on myeloid cells promotes tumor development" (2019-2023; 474.650,00€); project number: 21509
- 2018_ **PRIN2017** (Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale): coordinator of research unit of the project entitled: "Novel IDO1 inhibitors at the forefront of

cancer immunotherapy: from compound screening to preclinical validation in pancreatic ductal adenocarcinoma and glioblastoma multiforme” (2019-2021; 190.000,00€); project number: 2017WJZ9W9.

BOOKS

- De Sanctis F., Bronte V, **Ugel S.** *Tumor-induced Myeloid-derived Suppressor Cells*. In: Myeloid Cells in Health and Disease: A Synthesis, 2015, ASM Press.

PUBLICATION

1. Jacquelot N., Yamazaki T., Roberti M.P., Duong C.P.M., Andrews M.C., Verlingue L., Ferrere G., Becharef S., Vétizou M., Daillère R., Messaoudene M., Enot D.P., Stoll G., **Ugel S.**, Marigo I., Foong Ngiow S., Marabelle A., Prevost-Blondel A., Gaudreau P.O., Gopalakrishnan V., Eggermont A.M., Opolon P., Klein C., Madonna G., Ascierto P.A., Sucker A., Schadendorf D., Smyth M.J., Soria J.C., Kroemer G., Bronte V., Wargo J. and Zitvogel L. *Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade*. Cell Res. 2019 Sep 3. PMID:31481761
2. Canè S., **Ugel S.**, Trovato R., Marigo I., De Sanctis F., Sartoris S. and Bronte V. *The Endless Saga of Monocyte Diversity*. Front Immunol. 2019 Aug 6;10:1786. PMID:31447834
3. Filippini D., Agosto S., Delfino P., Simbolo M., Piro G., Rusev B., Veghini L., Cantù C., Lupo F., **Ugel S.**, De Sanctis F., Bronte V., Milella M., Tortora G., Scarpa A., Carbone C. and Corbo V. *Immuno-evolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease* Sci Rep. 2019 Aug 22;9(1):12286. PMID:31439856
4. Bertelli G., Trovato R., **Ugel S.**[#], Bria E., Milella M., Bronte V. and Pilotto S. Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report. Clin Lung Cancer. 2019 Apr 28. PMID:31122866 ([#]corresponding author)
5. Travelli C., Consonni F.M., Sangaletti S., Storto M., Morlacchi S., Grolla A.A., Galli U., Tron G.C., Portararo P., Rimassa L., Pressiani T., Mazzone M., Trovato R., **Ugel S.**, Bronte V., Tripodo C., Colombo M.P., Genazzani A.A. and Sica A. Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. Cancer Res. 2019 Feb 18. PMID: 30777853
6. Fiore A. *, **Ugel S.***, De Sanctis F., Sandri S., Fracasso G., Trovato R., Sartoris S., Solito S., Mandruzzato S., Vascotto F., Hippen K.L., Mondanelli G., Grohmann U., Piro G., Carbone C., Melisi D., Lawlor R.T., Scarpa A., Lamolinara A., Iezzi M., Fassan M., Biciato S., Blazar B.R., Sahin U., Murray P.J. and Bronte V. Induction of immunosuppressive functions and NF-κB by FLIP in monocytes. Nat Commun. 2018 Dec 5;9(1):5193. PMID:30518925 (* equal contribution)
7. Solito S., Pinton L., De Sanctis F., **Ugel S.**, Bronte V., Mandruzzato S., Marigo I. Methods to Measure MDSC Immune Suppressive Activity In Vitro and In Vivo. Curr Protoc Immunol. 2018 Oct 10:e61. PMID: 30303619

8. Dugnani E., Pasquale V., Marra P., Liberati D., Canu T., Perani L., De Sanctis F., **Ugel S.**, Invernizzi F., Citro A., Venturini M., Doglioni C., Esposito A., Piemonti L. Four-class tumor staging for early diagnosis and monitoring of murine pancreatic cancer using magnetic resonance and ultrasound. *Carcinogenesis*. 2018 Sep 21;39(9):1197-1206. PMID: 30052815
9. Boschi F., De Sanctis F, **Ugel S**, Spinelli AE. *T-cell tracking using Cerenkov and Radioluminescence imaging*. *J Biophotonics*. 2018 May 16:e201800093. PMID: 29770603
10. De Sanctis F, Sandri S, Martini M, Mazzocco M, Fiore A, Trovato R, Garetto S, Brusa D, **Ugel S**, Sartoris S. *Hyperthermic treatment at 56 °C induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens*. *Vaccine*. 2018 Jun 14;36(25):3708-3716. PMID:29752021
11. De Sanctis F, **Ugel S**, Facciponte J, Facciabene A. *The dark side of tumor-associated endothelial cells*. *Semin Immunol*. 2018 Feb;35:35-47. PMID: 29490888
12. De Sanctis F, Trovato R, **Ugel S**. *Anti-telomerase T cells adoptive transfer*. *Aging*. 2017 Nov 30;9(11):2239-2240. PMID:29190214
13. Sandri S, De Sanctis F, Lamolinara A, Boschi F, Poffe O, Trovato R, Fiore A, Sartori S, Sbarbati A, Bondanza A, Cesaro S, Krampera M, Scupoli MT, Nishimura MI, Iezzi M, Sartoris S, Bronte V, **Ugel S**. *Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy*. *Oncotarget*. 2017 May 23;8(50):86987-8700 PMID: 29152058
14. Mondanelli G., **Ugel S.**, Grohmann U., Bronte V. *The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO*. *Curr Opin Pharmacol*. 2017 May 26;35:30-39. PMID: 28554057
15. Giardino A., Innamorati G., **Ugel S.**, Perbellini O., Girelli R., Frigerio I., Regi P., Scopelliti F., Butturini G., Paiella S., Bacchion M., Bassi C. *Immunomodulation after radiofrequency ablation of locally advanced pancreatic cancer by monitoring the immune response in 10 patients*. *Pancreatology*. 2017 Sep 27. pii: S1424-3903(17)30851-7. PMID: 29037917
16. Mondanelli G., Bianchi R., Pallotta M.T., Orabona C., Albin E., Iacono A., Belladonna M.L., Vacca C., Fallarino F., Macchiarulo A., **Ugel S.**, Bronte V., Gevi F., Zolla L., Verhaar A., Peppelenbosch M., Mazza E.M., Bicciato S., Laouar Y., Santambrogio L., Puccetti P., Volpi C. and Grohmann U. *A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells*. *Immunity*. 2017 Feb 21;46(2):233-244. PMID: 28214225
17. Malpeli G., Barbi S., Zupo S., Tosadori G., Scardoni G., Bertolaso A., Sartoris S., **Ugel S.**, Vicentini C., Fassan M., Adamo A., Krampera M., Scupoli M.T., Croce C.M. and Scarpa A. *Identification of microRNAs implicated in the late differentiation stages of normal B cells suggests a central role for miRNA targets ZEB1 and TP53*. *Oncotarget*. 2017 Feb 14;8(7):11809-11826. PMID: 28107180
18. Marigo I., Zilio S., Desantis G., Mlecnik B., Agnellini A.H., **Ugel S.**, Sasso M.S., Qualls J.E., Kratochvill F., Zanovello P., Molon B., Ries C.H., Runza V., Hoves S., Bilocq A.M., Bindea G., Mazza E.M., Bicciato S., Galon J., Murray P.J. and Bronte V. *T Cell Cancer Therapy Requires*

CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. Cancer Cell. 2016 Sep 12;30(3):377-90. PMID: 27622331

19. De Sanctis F., Bronte V. and **Ugel S.** *Tumor-Induced Myeloid-Derived Suppressor Cells.* Microbiol Spectr. 2016 Jun;4(3). PMID:27337449.
20. Sandri S., Bobisse S., Moxley K., Lamolinara A., De Sanctis F., Boschi F., Sbarbati A., Fracasso G., Ferrarini G., Hendriks R.W., Cavallini C., Scupoli M.T., Sartoris S., Iezzi M., Nishimura M.I., Bronte V.* and **Ugel S.*** *Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies.* Cancer Res. 2016 May 1;76(9):2540-51. PMID: 27197263. (* equal contribution)
21. **Ugel S.**, De Sanctis F., Mandruzzato S. and Bronte V. *Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.* J Clin Invest. 2015 Sep;125(9):3365-76. PMID: 26325033.
22. **Ugel S.***, Facciponte J.G.*, De Sanctis F. and Facciabene A. *Targeting tumor vasculature: expanding the potential of DNA cancer vaccines.* Cancer Immunol Immunother. 2015 Oct;64(10):1339-48. PMID: 26267042. (* equal contribution)
23. De Sanctis F., Solito S., **Ugel S.**, Molon B., Bronte V. And Marigo I. *MDSCs in cancer: Conceiving new prognostic and therapeutic targets.* Biochim Biophys Acta. 2016Jan;1865(1):35-48. PMID: 26255541.
24. Mazzocco M., Martini M., Rosato A., Stefani E., Matucci A., Dalla Santa S., De Sanctis F., **Ugel S.**, Sandri S., Ferrarini G., Cestari T., Ferrari S., Zanovello P., Bronte V. and Sartoris S. *Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.* Immunology. 2015 Sep;146(1):33-49. PMID: 25959091.
25. Ricci C., Mota C., Moscato S., D'Alessandro D., **Ugel S.**, Sartoris S., Bronte V., Boggi U., Campani D., Funel N., Moroni L. and Danti S. *Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models.* Biomatter. 2014;4:e955386PMID:25482337.
26. Facciponte J.G.*, **Ugel S. ***, De Sanctis F., Li C, Wang L., Nair G., Sehgal S., Raj A., Matthaiou E., Coukos G. and Facciabene A. *Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature.* J Clin Invest. 2014 Apr;124(4):1497-511. PMID: 24642465. (* equal contribution)
27. De Sanctis F., Sandri S., Ferrarini G., Pagliarello I., Sartoris S., **Ugel S.**, Marigo I., Molon B. And Bronte V. *The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment.* Front Immunol. 2014 Feb 24;5:69. PubMed PMID: 24605112
28. **Ugel S.***, Peranzoni E.*, Desantis G., Chioda M., Walter S., Weinschenk T., Ochando J.C., Cabrelle A., Mandruzzato S. and Bronte V. *Immune tolerance to tumor antigens occurs in a specialized environment of the spleen.* Cell Rep. 2012 Sep 27;2(3):628-39. PMID: 22959433. (* equal contribution)

29. Molon B.*, **Ugel S.***, Del Pozzo F., Soldani C., Zilio S., Avella D., De Palma A., Mauri P., Monegal A., Rescigno M., Savino B., Colombo P., Jonjic N., Pecanic S., Lazzarato L., Fruttero R., Gasco A., Bronte V. and Viola A. *Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.* J Exp Med. 2011 Sep 26;208(10):1949-62. PMID: 21930770. (* equal contribution)
30. Marigo I., Bosio E., Solito S., Mesa C., Fernandez A., Dolcetti L., **Ugel S.**, Sonda N., Biciato S., Falisi E., Calabrese F., Basso G., Zanovello P., Cozzi E., Mandruzzato S. and Bronte V. *Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.* Immunity. 2010 Jun 25;32(6):790-802. PubMed PMID: 20605485.
31. Martini M., Testi M.G., Pasetto M., Picchio M.C., Innamorati G., Mazzocco M., **Ugel S.**, Cingarlini S., Bronte V., Zanovello P., Krampera M., Mosna F., Cestari T., Riviera A.P., Brutti N., Barbieri O., Matera L., Tridente G., Colombatti M. and Sartoris S. *IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer.* Vaccine. 2010 Apr 30;28(20):3548-57. PMID: 20304037.
32. Dolcetti L., Peranzoni E., **Ugel S.**, Marigo I., Fernandez Gomez A., Mesa C., Geilich M., Winkels G., Traggiati E., Casati A., Grassi F. and Bronte V. *Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.* Eur J Immunol. 2010 Jan;40(1):22-35. PMID: 19941314.
33. **Ugel S.***, Zoso A.*, De Santo C.*, Li Y., Marigo I., Zanovello P., Scarselli E., Cipriani B., Oelke M., Schneck J.P. and Bronte V. *In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.* Cancer Res. 2009 Dec 15;69(24):9376-84. PMID: 19934317. (* equal contribution)
34. **Ugel S.***, Scarselli E.*, Iezzi M., Mennuni C., Pannellini T., Calvaruso F., Cipriani B., De Palma R., Ricci-Vitiani L., Peranzoni E., Musiani P., Zanovello P. and Bronte V. *Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes.* Blood. 2010 Feb 18;115(7):1374-84. PMID: 19903903. (* equal contribution)
35. **Ugel S.**, Delpozzo F., Desantis G., Papalini F., Simonato F., Sonda N., Zilio S. And Bronte V. *Therapeutic targeting of myeloid-derived suppressor cells.* Curr Opin Pharmacol. 2009 Aug;9(4):470-81. Review. PMID: 19616475.
36. Mennuni C.*, **Ugel S.***, Mori F., Cipriani B., Iezzi M., Pannellini T., Lazzaro D., Ciliberto G., La Monica N., Zanovello P., Bronte V. and Scarselli E. *Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer.* Cancer Res. 2008 Dec 1;68(23):9865-74. PMID: 19047167. (* equal contribution)
37. Peranzoni E., Marigo I., Dolcetti L., **Ugel S.**, Sonda N., Taschin E., Mantelli B., Bronte V. and Zanovello P. *Role of arginine metabolism in immunity and immunopathology.* Immunobiology. 2007;212(9-10):795-812. PMID: 18086380.
38. Bronte V., Cingarlini S., Marigo I., De Santo C., Gallina G., Dolcetti L., **Ugel S.**, Peranzoni E., Mandruzzato S. and Zanovello P. *Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention.* Immunol Invest. 2006;35(3-4):327-57. PMID: 16916757.

The scientific research activity of Dr. Stefano Ugel is proved by different bibliographic indexes:

SCOPUS:

Documenti: 39

Hirsch h index: 18

Citations: 2101

<https://www.scopus.com/>

Web of Science:

Documenti: 40

Hirsch h index: 19

Citations: 1984

http://apps.webofknowledge.com/WOS_GeneralSearch_input.do?product=WOS&search_mode=GeneralSearch&SID=Q2nhFMu6oynPK5ojF9M&preferencesSaved=

Google Scholar:

Documenti: 50

Hirsch h index: 18

Citations: 2822

<https://scholar.google.com/citations?hl=it&user=3UAgDJEAAAAJ>

DIDATIC ACTIVITY

Teaching activity:

2016-up now: Professor of Immunology at course of Bachelor's degree in Biomedical Laboratory Techniques (to qualify as a biomedical laboratory worker) (CFU: 1);

2016-up now: Professor of Immunology at course of Combined Bachelor's + Master's degree in Dentistry and Dental Prosthetics (CFU: 3);

2017-up now: Professor of Sciences introduction to the medical profession at course of Combined Bachelor's + Master's degree in Medicine and Surgery (CFU: 1);

2017-up now: Professor of Systematic pathology I at course of Combined Bachelor's + Master's degree in Medicine and Surgery (CFU: 1);

2017-up now: Professor of Immunology at course of Bachelor's degree in Biotechnology (CFU: 6).

Academic Assignments:

1) Council member for the Degree Course in Biomedical Laboratory Techniques - Medicine and Surgery; Department of Medicine, University of Verona.

2) Council member for the PhD program Inflammation, Immunity and Cancer; Department of Medicine, University of Verona

3) Council member for the Degree in Biotechnology, Department of Biotechnology, University of Verona

4) Council member of Grad School of Allergology and Immunology, Department of Medicine, University of Verona

5) Council member (L2) of Department of Medicine, University of Verona

Academic Commission:

- 1) Member of commission for the final evaluation of PhD students of Inflammation, Immunity and Cancer course (a.a.2018-2019).
- 2) Member of commission for the final evaluation of Master degree in Medicine and Surgery (a.a. 2016-2017)
- 3) Member of commission for the final evaluation of Master degree in Molecular and Medical Biotechnology (a.a. 2016-2017)
- 4) Member of commission for the final evaluation of Master degree in Dentistry and Dental Prosthetics (a.a. 2016-2017)
- 5) Member of commission for the final evaluation of Bachelor degree in Biotechnology (a.a. 2018-2019)

Firma

A handwritten signature in black ink, appearing to read 'Stefano Ugel', written in a cursive style with a large initial 'S'.

Il sottoscritto è consapevole Stefano Ugel: di essere penalmente sanzionabile se rilascia falsa dichiarazione (art. 76 D.P.R. 445/2000), di decadere dei benefici conseguiti di un provvedimento adottato sulla base delle false dichiarazioni art. 75 D.P.R. n. 445/2000; che l'amministrazione si riserva di controllare la veridicità delle dichiarazioni rese (art. 71 D.P.R. 445/2000); che i dati forniti dal dichiarante saranno utilizzati solo ai fini del procedimento richiesto (D.L. vo n. 0196/2003)